Previous 10 |
home / stock / mpsyy / mpsyy news
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 21, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conference: 8th Annual Leerink Partners Global Healthcare Conference Date: February 28, 2019, 2:30 pm EST (8:30 pm ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 19, 2019 / Simon Moroney, CEO and co-founder of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; NASDAQ: MOR), informed the Company's Supervisory Board today that he has decided not to renew his contract as a member of the...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 19, 2019 / Simon Moroney, CEO and co-founder of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; NASDAQ: MOR), informed the Company's Supervisory Board today that he has decided not to renew his contract as a member of the...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 5, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; NASDAQ: MOR) today announced the appointment of David R. Trexler as President and member of the Board of Directors of MorphoSys US Inc., effective February 6, 2019...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 26, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announces that it was informed today that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware, ba...
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Sp/Adr Company Name:
MPSYY Stock Symbol:
OTCMKTS Market:
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 24, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced that its Supervisory Board has today appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer (CEO). The appointment will take effec...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 22, 2019 / MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019. MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today p...
Conference call and webcast (in English) to be held on May 8, 2019 at 2:00pm CEST (1:00pm BST/8:00am EDT) - MOR208: Rolling submission of L-MIND study data to FDA to support potential approval in the U.S. on track - David Trexler hired as President, MorphoSys US Inc.; build-up of c...